- Nachrichtendetail
-
29.05.2024 04:09:38 - dpa-AFX: Merck Nears $1.3 Bln Cash Deal To Buy EyeBio, With Potential $1.7 Bln In Milestone Payments : Report
KENILWORTH (NJ) (dpa-AFX) - Merck & Co., Inc. (MRK) is nearing an agreement
to buy a privately held ophthalmology biotechnology company Eyebiotech for $1.3
billion in cash, the Wall Street Journal reported citing people familiar with
the matter.
According to the report, Merck could make an additional $1.7 billion in
milestone payments for EyeBio. The deal could be announced as early as
Wednesday. Merck's venture arm was an investor in EyeBio.
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
to buy a privately held ophthalmology biotechnology company Eyebiotech for $1.3
billion in cash, the Wall Street Journal reported citing people familiar with
the matter.
According to the report, Merck could make an additional $1.7 billion in
milestone payments for EyeBio. The deal could be announced as early as
Wednesday. Merck's venture arm was an investor in EyeBio.
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
| Name | WKN | Börse | Kurs | Datum/Zeit | Diff. | Diff. % | Geld | Brief | Erster | Schluss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
Merck & Co | A0YD8Q | NYSE | 128,570 | 28.06.24 20:39:22 | -1,250 | -0,96% | 128,560 | 128,580 | 131,990 | 129,820 |
